A new research review indicates that GLP-1 receptor agonists, including Zepbound, can help reduce obstructive sleep apnea symptoms in patients with obesity by promoting weight loss.
Key facts
- •Zepbound is the only weight loss medication currently FDA-approved for treating moderate to severe OSA in adults with obesity.
- •In SURMOUNT-OSA phase 3 trials, tirzepatide reduced AHI by 20 to 24 events per hour compared to a placebo.
- •Researchers found that 42% to 50% of patients in the SURMOUNT-OSA trials reached disease remission.
- •Experts warn that GLP-1 treatment can cost approximately $1,000 per month, with insurance coverage varying by provider.
- •Losing 10% of body weight is associated with a 26% reduction in the apnea-hypopnea index.
A research review published in JAMA Otolaryngology on September 3 suggests that GLP-1 receptor agonists, such as tirzepatide, may significantly improve obstructive sleep apnea (OSA) associated with obesity. While CPAP therapy remains the standard treatment, the study indicates these medications can reduce breathing interruptions by promoting fat loss in the neck, throat, and tongue. Zepbound is currently the only weight loss drug FDA-approved specifically for treating OSA in adults with obesity.
By the numbers
Clinical Findings and Mechanisms
The review analyzed studies published between 2016 and 2025, finding that tirzepatide reduced the apnea-hypopnea index (AHI) by 20 to 24 events per hour in clinical trials. Up to half of study participants achieved full symptom remission. Researchers noted that these improvements often appeared as early as four weeks into treatment, suggesting benefits may extend beyond weight loss alone, potentially involving stabilization of respiratory control systems and anti-inflammatory effects.
Medical Guidance on Treatment
Medical experts emphasize that GLP-1 medications should not be viewed as a cure for OSA, as anatomical issues unrelated to fat deposits may persist. Patients are advised to continue CPAP therapy until a physician confirms remission via a follow-up sleep study. Experts suggest that GLP-1s may serve as a useful supplement for patients who struggle with CPAP adherence or who require weight loss to become candidates for other procedures, such as hypoglossal nerve stimulation.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
